AQR Capital Management LLC decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 1.4% during the first quarter, Holdings Channel reports. The firm owned 1,231,386 shares of the medical equipment provider’s stock after selling 18,083 shares during the period. AQR Capital Management LLC’s holdings in Hologic were worth $52,395,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the company. State Street Corp increased its position in Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock valued at $540,846,000 after buying an additional 189,572 shares during the last quarter. Victory Capital Management Inc. increased its position in Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares during the last quarter. Bank of Montreal Can increased its position in Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares during the last quarter. American Century Companies Inc. increased its position in Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Hologic by 6.4% in the first quarter. Geode Capital Management LLC now owns 3,116,366 shares of the medical equipment provider’s stock valued at $132,440,000 after buying an additional 186,854 shares during the last quarter. 94.47% of the stock is owned by institutional investors and hedge funds.
Hologic, Inc. (NASDAQ:HOLX) traded down 0.52% during trading on Friday, reaching $46.25. The company’s stock had a trading volume of 2,320,363 shares. The firm has a 50-day moving average price of $44.24 and a 200-day moving average price of $41.90. The firm has a market capitalization of $12.95 billion, a P/E ratio of 16.58 and a beta of 0.94. Hologic, Inc. has a 52 week low of $32.81 and a 52 week high of $46.54.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.46 by $0.04. The company had revenue of $715.40 million for the quarter, compared to analysts’ expectations of $685.24 million. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The firm’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 earnings per share. On average, equities analysts anticipate that Hologic, Inc. will post $2.01 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was published by sleekmoney and is the sole property of of sleekmoney. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://sleekmoney.com/aqr-capital-management-llc-decreases-position-in-hologic-inc-holx/1935037.html.
Several research firms recently weighed in on HOLX. Barclays PLC set a $50.00 price objective on Hologic and gave the company a “buy” rating in a research note on Wednesday, April 5th. Needham & Company LLC raised their price objective on Hologic from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, April 4th. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, March 29th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $49.00 price objective (up from $46.00) on shares of Hologic in a research note on Monday, March 13th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $53.00 price objective on shares of Hologic in a research note on Tuesday, May 9th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Hologic currently has an average rating of “Buy” and a consensus target price of $47.54.
In other Hologic news, Director Elaine Ullian sold 9,104 shares of the company’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $42.40, for a total value of $386,009.60. Following the transaction, the director now owns 23,810 shares of the company’s stock, valued at $1,009,544. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lawrence M. Levy sold 2,960 shares of the company’s stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $44.54, for a total value of $131,838.40. Following the completion of the transaction, the director now directly owns 45,634 shares in the company, valued at approximately $2,032,538.36. The disclosure for this sale can be found here. Insiders sold 118,252 shares of company stock worth $5,158,821 in the last ninety days. 0.79% of the stock is owned by corporate insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/aqr-capital-management-llc-decreases-position-in-hologic-inc-holx/1935037.html
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.